Mirati Therapeutics Inc. announced that the first patient has been dosed in its phase one clinical study for the treatment of patients with advanced solid tumors.

The treatment, MGCD516, is a receptor tyrosine kinase inhibitor with molecular targets that act as a genetic drivers for cancer progression.

“This study is designed to identify an optimal dose and move quickly into expansion cohorts in selected patients who have genetic alterations of certain kinases,” said Charles Baum, president and CEO of Mirati. “By focusing on patients that harbor these genetic drivers of disease, we believe MGCD516 will be more likely to demonstrate a high response rate in defined patient subsets, with the potential to support an accelerated development path.”

Mirati is an oncology company developing medicines for precisely defined patient populations.